

Match Overview

1	Crossref 121 words Lakshini Y. Herat, Aaron L. Magno, Caroline Rudnicka, Jan... Hricova et al. "SGLT2 Inhibitor-Induced Sympathoinhibition";	3%
2	Internet 31 words creativecommons.org	1%
3	Crossref 21 words Si Tan, Jose A. Caparros-Martin, Vance B. Matthews, Henrieta Koch, Fergal O'Gara, Kevin D. Croft, Natalie C. Ward. "Iso	1%
4	Internet 14 words crawled on 01-Jun-2019 www.medicaid.nv.gov	<1%
5	Internet 12 words crawled on 13-May-2020 slideheaven.com	<1%

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 54999

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Sodium Glucose Co-transporter 2 inhibition reduces succinate levels in diabetic mice

Herat LY *et al.* SGLT2 inhibition reduces succinate levels.

Abstract

BACKGROUND

Type 1 diabetes (T1D) is associated with major chronic microvascular complications which contribute significantly to diabetes associated morbidity. The protein primarily responsible for glucose reabsorption in the kidney is sodium glucose co-transporter 2 (SGLT2). Presently, SGLT2 inhibitors are widely used in diabetic patients to improve blood glucose levels and prevent cardiovascular and renal complications. Given the

low side effect profile of SGLT2 inhibitors, it is hypothesized that SGLT2

SGLT2 inhibition reduces succinate levels and promote:



ALL

IMAGES

VIDEOS

26,400 Results

Any time ▼

(PDF) SGLT2 inhibition in diabetes mellitus: Rationale and ...

https://www.researchgate.net/publication/221811247_SGLT2_inhibition_in_diabetes..

.

Sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated **reduced HbA1c** and **lower glucose variability** with ...

Canagliflozin, an SGLT2 inhibitor, attenuates the ...

<https://www.nature.com/articles/s41598-018-19658-7>

Feb 05, 2018 · **Sodium glucose cotransporter 2 (SGLT2) inhibitors**, an antidiabetic drug, **promotes urinary excretion** of **glucose** by blocking its reabsorption in the **renal proximal tubules**. It is unclear whether **SGLT2 inhibition** could **attenuate nonalcoholic steatohepatitis (NASH)** and NASH-associated **hepatocellular carcinoma**.

Cited by: 27

Author: Kumiko Shiba, Kyoichiro Tsuchiya, Chik...

Publish Year: 2018

(PDF) SGLT2 inhibition via dapagliflozin improves ...

https://www.researchgate.net/publication/324807875_SGLT2_inhibition_via_dapagliflozin...

SGLT2 **inhibition** via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota **in type 2 diabetic mice** Article (PDF Available) in Cardiovascular Diabetology 17(1 ...

The histone deacetylase inhibitor butyrate improves ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693467>

Aug 20, 2015 · The histone deacetylase **inhibitor butyrate** improves metabolism and **reduces** muscle atrophy during aging Michael E. Walsh , 1 Arunabh Bhattacharya , 1 , 2 Kavithalakshmi Sataranatarajan , 3 Rizwan Qaisar , 3 Lauren Sloane , 2 , 4 Md M. Rahman , 1 Michael Kinter , 3 and Holly Van Remmen 3

Cited by: 74

Author: Michael E. Walsh, Arunabh Bhattachary...

Publish Year: 2015

国内版

国际版

Sodium Glucose Co-transporter 2 inhibition reduces succinate lev



Q ALL

IMAGES

VIDEOS

38,500 Results

Any time ▾

[Sodium-glucose co-transporter 2 inhibition with ...](#)

<https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.1473>

Apr 29, 2019 · **Sodium-glucose co-transporter 2 (SGLT2) inhibition reduces heart failure hospitalizations** in patients with **diabetes**, irrespective of glycaemic control. We examined the effect of **SGLT2 inhibition** with empagliflozin (EMPA) on **cardiac function** in non-**diabetic rats** with left **ventricular (LV) dysfunction** after myocardial infarction (MI).

Cited by: 25

Author: Salva R. Yurista, Herman H.W. Silljé, Silke U...

Publish Year: 2019

[Sodium-glucose co-transporter 2 inhibition with ...](#)

<https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1473>

Apr 29, 2019 · **Sodium-glucose co-transporter 2 (SGLT2) inhibition reduces heart failure hospitalizations** in patients with **diabetes**, irrespective of glycaemic control. We examined the effect of **SGLT2 inhibition** with empagliflozin (EMPA) on **cardiac function** in non-**diabetic rats** with left **ventricular (LV) dysfunction** after myocardial infarction (MI).

Cited by: 25

Author: Salva R. Yurista, Herman H.W. Silljé, Silke U...

Publish Year: 2019

[Sodium-Glucose Cotransporter 2 Inhibitors: A ... - Diabetes](#)

<https://diabetes.diabetesjournals.org/content/68/6/1109> ▾

Jun 01, 2019 · **Ketoacidosis. SGLT2 inhibitors increase ketone body levels** in healthy volunteers and **patients** with type 2 **diabetes** (45, 47). In a small subpopulation of patients with type 2 **diabetes**, **ketone body levels increase** to the point where they cause ketoacidosis (63, 64).

Cited by: 7

Author: Amber L. Beitelshees, Bruce R. Leslie, Sime...

Publish Year: 2019

[ALL](#) [IMAGES](#) [VIDEOS](#) [MAPS](#) [NEWS](#) [SHOPPING](#)

45,000 Results

Any time ▾

[Sodium–glucose co-transporter 2 inhibition with ...](#)

<https://onlinelibrary.wiley.com> › [doi](#) › [abs](#) › [10.1002](#) › [ejhf.1473](#)

Apr 29, 2019 · **Sodium–glucose co-transporter 2 (SGLT2) inhibition reduces heart failure hospitalizations** in patients with **diabetes**, irrespective of glycaemic control. We examined the effect of **SGLT2 inhibition** with empagliflozin (EMPA) on **cardiac function** in non-**diabetic rats** with left **ventricular (LV) dysfunction** after myocardial infarction (MI).

Cited by: 25**Author:** Salva R. Yurista, Herman H.W. Silljé, Silk...**Publish Year:** 2019

[Sodium–glucose co-transporter 2 inhibition with ...](#)

<https://onlinelibrary.wiley.com> › [doi](#) › [full](#) › [10.1002](#) › [ejhf.1473](#)

Apr 29, 2019 · **Sodium–glucose co-transporter 2 (SGLT2) inhibition reduces** heart failure hospitalizations in patients with **diabetes**, irrespective of glycaemic control. We examined the effect of **SGLT2 inhibition** with empagliflozin (EMPA) on cardiac function in non-diabetic rats with left ventricular (LV) dysfunction after myocardial infarction (MI).

Cited by: 25**Author:** Salva R. Yurista, Herman H.W. Silljé, Silk...**Publish Year:** 2019

[Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor ...](#)

<https://www.ncbi.nlm.nih.gov> › [pmc](#) › [articles](#) › [PMC4786146](#)

Mar 10, 2016 · Dapagliflozin, a **Sodium-Glucose Co-Transporter 2 Inhibitor**, Acutely **Reduces** Energy Expenditure in BAT via Neural Signals in **Mice** Yumiko Chiba , 1 Tetsuya Yamada , 1, * Sohei Tsukita , 1 Kei Takahashi , 1 Yuichiro Munakata , 1 Yuta Shirai , 1 Shinjiro Kodama , 1 Yoichiro Asai , 1 Takashi Sugisawa , 1 Kenji Uno , 1 Shojiro Sawada , 1 Junta Imai ...

Cited by: 17**Author:** Yumiko Chiba, Tetsuya Yamada, Sohei Ts...**Publish Year:** 2016

[Sodium–Glucose Cotransporter 2 Inhibition and Diabetic ...](#)

<https://diabetes.diabetesjournals.org> › [content](#) › [68](#) › [2](#) › [248](#)

Feb 01, 2019 · Diabetic kidney disease (DKD) is now the principal cause of chronic kidney disease leading to end-stage kidney disease worldwide. As a primary contributor to the excess risk of all-cause